Latrepirdine

Generic Name: Latrepirdine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅N_₃

CAS Number: 3613-73-8

Unique Ingredient Identifier: OD9237K1Z6

Background: Latrepirdine has been investigated for the treatment of Alzheimer's Disease and Huntington's Disease.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

An Extension of the CONCERT Protocol (DIM18)

Phase 3

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Dimebon

First Posted Date: 2010-06-29

Last Posted Date: 2016-09-27

Lead Sponsor: Medivation, Inc.

Target Recruit Count: 672

Registration Number: NCT01152216

A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users

Phase 1

Completed

Conditions: Alzheimer's Disease
Huntington's Disease

Interventions: Drug: placebo
Drug: alprazolam
Drug: dimebon

First Posted Date: 2009-09-11

Last Posted Date: 2013-04-02

Lead Sponsor: Pfizer

Target Recruit Count: 36

Registration Number: NCT00975481

An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease

Phase 3

Terminated

Conditions: Alzheimer's Disease

Interventions: Drug: Dimebon

First Posted Date: 2009-07-15

Last Posted Date: 2012-11-14

Lead Sponsor: Pfizer

Target Recruit Count: 649

Registration Number: NCT00939783

Locations: 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico

A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease

Phase 3

Completed

Conditions: Huntington Disease

Interventions: Drug: Dimebon
Other: Placebo

First Posted Date: 2009-06-15

Last Posted Date: 2016-10-12

Lead Sponsor: Medivation, Inc.

Target Recruit Count: 403

Registration Number: NCT00920946

A Phase 1 Trial To Assess The Safety And Pharmacokinetics Of Single, Ascending, Oral Doses Of Dimebon In Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Dimebon

First Posted Date: 2009-05-22

Last Posted Date: 2009-07-22

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00907322

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: Dimebon

First Posted Date: 2009-02-06

Last Posted Date: 2018-12-06

Lead Sponsor: Pfizer

Target Recruit Count: 742

Registration Number: NCT00838110

Locations: 🇵🇷
Pfizer Investigational Site, San Juan, Puerto Rico

Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function

Phase 1

Completed

Conditions: Hepatic Failure

Interventions: Drug: Dimebon

First Posted Date: 2009-01-29

Last Posted Date: 2009-09-16

Lead Sponsor: Pfizer

Target Recruit Count: 23

Registration Number: NCT00831532

Locations: 🇺🇸
Pfizer Investigational Site, Indianapolis, Indiana, United States

Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

Phase 1

Completed

Conditions: Alzheimer Disease
Huntington Disease

Interventions: Drug: digoxin
Drug: dimebon

First Posted Date: 2009-01-29

Last Posted Date: 2009-06-12

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00831506

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Dimebon
Drug: Placebo comparator

First Posted Date: 2009-01-27

Last Posted Date: 2016-09-27

Lead Sponsor: Medivation, Inc.

Target Recruit Count: 1003

Registration Number: NCT00829374

Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo
Drug: Dimebon

First Posted Date: 2009-01-27

Last Posted Date: 2015-11-10

Lead Sponsor: Medivation, Inc.

Target Recruit Count: 46

Registration Number: NCT00829816

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy